Patient Navigation in Amyotrophic Lateral Sclerosis (ALS): A Potential Approach to Timely Diagnosis

被引:0
|
作者
Mombaur, Busisiwe [1 ]
Dias, Kaiseree [2 ]
机构
[1] Columbia Univ, Neurol Inst, 710 West 168th St, New York, NY 10032 USA
[2] Univ Bristol, Bristol Med Sch, Dept Populat Hlth Sci, Bristol, England
关键词
Patient navigation; amyotrophic lateral sclerosis; delayed diagnosis; ALS; CANCER CARE; DISEASE; HEALTH; IMPACT;
D O I
10.1353/hpu.2025.a951602
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Amyotrophic lateral sclerosis (ALS) poses challenges for timely diagnosis due to its protean early manifestations and lack of definitive tests. This article explores how patient navigation interventions can expedite diagnosis, particularly for underserved patients who face disproportionately longer delays. Patient navigation has proven effective in reducing disparities in various diseases by providing guidance and support to patients and caregivers. It enhances awareness, facilitates communication with health care providers, and streamlines diagnosis. Drawing from literature on patient navigation in other diseases, this article proposes tailored adaptations for ALS diagnosis and addresses potential implementation barriers and strategies to overcome them. Integrating patient navigation into the ALS diagnostic pathway holds promise for improving efficiency, optimizing outcomes, and reducing health care disparities among underserved populations.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Personalized Precision Immunotherapy for Amyotrophic Lateral Sclerosis (ALS)
    Maharaj, Dipnarine
    Kaur, Kawaljit
    Saltese, Adrian
    Gouvea, Jacqueline
    CRITICAL REVIEWS IN IMMUNOLOGY, 2023, 43 (02) : 1 - 11
  • [42] The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS)
    Sarah L. Boddy
    Ilaria Giovannelli
    Matilde Sassani
    Johnathan Cooper-Knock
    Michael P. Snyder
    Eran Segal
    Eran Elinav
    Lynne A. Barker
    Pamela J. Shaw
    Christopher J. McDermott
    BMC Medicine, 19
  • [43] Amyotrophic Lateral Sclerosis (ALS): An Overview of Genetic and Metabolic Signaling Mechanisms
    Nogueira-Machado, Jose Augusto
    Silva, Franscisco das Chagas
    Silva, Fabiana
    Gomes, Nathalia
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2025, 24 (02) : 83 - 90
  • [44] Perceptions of sexuality in individuals with Amyotrophic Lateral Sclerosis (ALS) and their treating clinicians
    Shahbazi, Mona
    Holzberg, Shara
    Thirunavukkarasu, Saeyoan
    Ciani, Gioia
    NEUROREHABILITATION, 2017, 41 (02) : 331 - 342
  • [45] Overview of Lipid Biomarkers in Amyotrophic Lateral Sclerosis (ALS)
    Trostchansky, Andres
    ROLE OF BIOACTIVE LIPIDS IN CANCER, INFLAMMATION AND RELATED DISEASES, 2019, 1161 : 233 - 241
  • [46] The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS)
    Boddy, Sarah L.
    Giovannelli, Ilaria
    Sassani, Matilde
    Cooper-Knock, Johnathan
    Snyder, Michael P.
    Segal, Eran
    Elinav, Eran
    Barker, Lynne A.
    Shaw, Pamela J.
    McDermott, Christopher J.
    BMC MEDICINE, 2021, 19 (01)
  • [47] Home care of patients with amyotrophic lateral sclerosis (ALS)
    Krivickas, LS
    Shockley, L
    Mitsumoto, H
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 152 : S82 - S89
  • [48] Stem cells in the treatment of amyotrophic lateral sclerosis (ALS)
    Silani, V
    Fogh, I
    Ratti, A
    Sassone, J
    Ciammola, A
    Cova, L
    AMYOTROPHIC LATERAL SCLEROSIS, 2002, 3 (04): : 173 - 181
  • [49] Amyotrophic lateral sclerosis (ALS): evaluation of respiratory function
    Perez, T.
    REVUE NEUROLOGIQUE, 2006, 162 : 4S188 - 4S194
  • [50] White matter injury in amyotrophic lateral sclerosis (ALS)
    Rafalowska, J
    Dziewulska, D
    FOLIA NEUROPATHOLOGICA, 1996, 34 (02): : 87 - 91